Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular responses to immune checkpoint blockade in glioblastoma.

Literature DB >> 30842671

Molecular responses to immune checkpoint blockade in glioblastoma.

Hirotaka Ito¹, Hiroshi Nakashima¹, E Antonio Chiocca².

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2019 PMID： 30842671 PMCID： PMC6742426 DOI： 10.1038/s41591-019-0385-7

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

13 in total

1. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors: Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal: Nature Date: 2018-12-19 Impact factor: 49.962

2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Authors: Kurt A Schalper; Maria E Rodriguez-Ruiz; Ricardo Diez-Valle; Alvaro López-Janeiro; Angelo Porciuncula; Miguel A Idoate; Susana Inogés; Carlos de Andrea; Ascensión López-Diaz de Cerio; Sonia Tejada; Pedro Berraondo; Franz Villarroel-Espindola; Jungmin Choi; Alfonso Gúrpide; Miriam Giraldez; Iosune Goicoechea; Jaime Gallego Perez-Larraya; Miguel F Sanmamed; Jose L Perez-Gracia; Ignacio Melero
Journal: Nat Med Date: 2019-02-11 Impact factor: 53.440

Review 3. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors: Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal: Neuro Oncol Date: 2018-10-01 Impact factor: 12.300

Review 4. Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Authors: Sylvia C Kurz; Patrick Y Wen
Journal: Curr Treat Options Neurol Date: 2018-04-18 Impact factor: 3.598

Review 5. Immune checkpoints and their inhibition in cancer and infectious diseases.

Authors: Lydia Dyck; Kingston H G Mills
Journal: Eur J Immunol Date: 2017-04-24 Impact factor: 5.532

Review 6. Treating recurrent glioblastoma: an update.

Authors: Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal: CNS Oncol Date: 2015

Review 7. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

Authors: E Antonio Chiocca; Farshad Nassiri; Justin Wang; Pierpaolo Peruzzi; Gelareh Zadeh
Journal: Neuro Oncol Date: 2019-01-01 Impact factor: 12.300

Review 8. Treatment of Glioblastoma.

Authors: Joo Yeon Nam; John F de Groot
Journal: J Oncol Pract Date: 2017-10 Impact factor: 3.840

9. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors: Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal: Nat Med Date: 2019-02-11 Impact factor: 53.440

10. IDH1 and IDH2 mutations in gliomas.

Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079

18 in total

1. Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

Authors: Yang Liu; Pakawat Chongsathidkiet; Bridget M Crawford; Ren Odion; Cosette A Dechant; Hanna R Kemeny; Xiuyu Cui; Paolo F Maccarini; Christopher D Lascola; Peter E Fecci; Tuan Vo-Dinh
Journal: Immunotherapy Date: 2019-09-18 Impact factor: 4.196

2. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Authors: E Antonio Chiocca; John S Yu; Rimas V Lukas; Isaac H Solomon; Keith L Ligon; Hiroshi Nakashima; Daniel A Triggs; David A Reardon; Patrick Wen; Brittany M Stopa; Ajay Naik; Jeremy Rudnick; Jethro L Hu; Priya Kumthekar; Bakhtiar Yamini; Jill Y Buck; Nathan Demars; John A Barrett; Arnold B Gelb; John Zhou; Francois Lebel; Laurence J N Cooper
Journal: Sci Transl Med Date: 2019-08-14 Impact factor: 17.956

3. Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway.

Authors: Peng Zhou; Maoxing Fei; Yanling Han; Mengliang Zhou; Handong Wang
Journal: Onco Targets Ther Date: 2020-08-04 Impact factor: 4.147

4. HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM).

Authors: Farzaneh Sharifzad; Soura Mardpour; Saeid Mardpour; Esmaeil Fakharian; Adeleh Taghikhani; Amirhossein Sharifzad; Sahar Kiani; Yasaman Heydarian; Marek J Łos; Zahra Azizi; Saeid Ghavami; Amir Ali Hamidieh; Marzieh Ebrahimi
Journal: Int J Mol Sci Date: 2020-03-25 Impact factor: 5.923